X
[{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"NewCo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FORMA Therapeutics Announces Divestiture of Select Hit Discovery Capabilities","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Announces FT-4202 Granted Fast Track Designation and Rare Pediatric Disease Designation for Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FORMA Therapeutics Receives FDA Orphan Drug Designation for FT-4202 for the Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Phase I Clinical Data for Investigational Agent FT-4202 in Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Forma Therapeutics Launches Proposed Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Four Oral and Poster Presentations on FT-4202 in Sickle Cell Disease at 2020 ASH Virtual Annual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Presents Clinical Proof-of-Concept Data Supporting the Potential of FT-4202 to Treat Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Presents New Phase 1 Data on Etavopivat at 26th European Hematology Association Congress","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Novo Nordisk to Acquire Forma Therapeutics and Expand Presence in Sickle Cell Disease and Rare Blood Disorders","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Novo Nordisk Announces the Completion of The Forma Therapeutics Acquisition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics\u2019 Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forma Therapeutics Announces Presentations at Upcoming Hematology Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Etavopivat
Filters
Companies By Therapeutic Area
Details:
The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat (FT-4202), is aligned with Novo Nordisk’s strategy to complement and accelerate its scientific presence and pipeline in haemoglobinopathies.
Lead Product(s):
Etavopivat
Therapeutic Area: Genetic Disease
Product Name: FT-4202
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Novo Nordisk
Deal Size: $1,100.0 million
Upfront Cash: $1,100.0 million
Deal Type: Acquisition
October 14, 2022
Details:
With the acquisition, Novo Nordisk will gain access to Forma’s lead development candidate, etavopivat being developed in SCD to expand presence in sickle cell disease, rare blood disorders and haemoglobinopathies.
Lead Product(s):
Etavopivat
Therapeutic Area: Hematology
Product Name: FT-4202
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Novo Nordisk
Deal Size: $1,100.0 million
Upfront Cash: $1,100.0 million
Deal Type: Acquisition
September 01, 2022
Details:
FT-4202 (etavopivat) is designed to activate PKR and thereby modulate RBC metabolism by impacting two critical pathways in RBCs, will investigate whether decreasing 2,3-DPG may help oxygen bind to hemoglobin and thereby increase ATP and impact RBC function.
Lead Product(s):
Etavopivat
Therapeutic Area: Genetic Disease
Product Name: FT-4202
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 10, 2022
Details:
Etavopivat, the company's investigational oral, once-daily, selective pyruvate kinase-R activator, significantly improved anemia and red blood cell health with a favorable tolerability and safety profile in patients with SCD.
Lead Product(s):
Etavopivat
Therapeutic Area: Genetic Disease
Product Name: FT-4202
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 11, 2021
Details:
E-poster presentation includes initial data from the open-label extension cohort showing etavopivat improved and sustained hematologic and hemolytic parameters for patients living with sickle cell disease receiving 400 mg etavopivat once-daily for at least 2 to 12 weeks.
Lead Product(s):
Etavopivat
Therapeutic Area: Genetic Disease
Product Name: FT-4202
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 11, 2021
Details:
Doubling the dose of FT-4202 to 600 mg daily for 14 days compared to the previous 300 mg cohort was well-tolerated with no dose-limiting toxicities or treatment-related adverse events observed.
Lead Product(s):
Etavopivat
Therapeutic Area: Genetic Disease
Product Name: FT-4202
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 30, 2021
Details:
Funds to be used in the development of its lead program FT-4202 in sickle cell disease and completion of Phase 1 clinical trial, advancement of FT-7051 in metastatic castration-resistant prostate cancer, pre-approval activities for FT-2102 in AML.
Lead Product(s):
Etavopivat
Therapeutic Area: Genetic Disease
Product Name: FT-4202
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Jefferies
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Public Offering
December 08, 2020
Details:
FT-4202 is a novel, investigational, selective red blood cell pyruvate kinase-R activator in development as a potential disease-modifying therapy for SCD. 6 of 7 (86%) patients on 300 mg of FT-4202 for 14 days achieved a hemoglobin increase > 1 g/dL from baseline.
Lead Product(s):
Etavopivat
Therapeutic Area: Genetic Disease
Product Name: FT-4202
Highest Development Status: Phase II/ Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 07, 2020
Details:
In a cohort of nine patients, six of seven patients (86%) who received FT-4202 achieved a hemoglobin increase of greater than 1 g/dL from baseline with once-daily dosing at 300 mg for 14 days.
Lead Product(s):
Etavopivat
Therapeutic Area: Genetic Disease
Product Name: FT-4202
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 07, 2020
Details:
European Commission granted Orphan Drug designation to Forma’s FT-4202 for the treatment of sickle cell disease (SCD), based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA).
Lead Product(s):
Etavopivat
Therapeutic Area: Genetic Disease
Product Name: FT-4202
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 10, 2020